Tax Authority demands NIS 2.7b from Teva

January 5, 2012 16:04
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Israel's Tax Authority has issued an assessment requiring Teva Pharmaceutical Industries Ltd. to pay NIS 2.7 billion regarding several matters related to the Law for the Encouragement of Capital Investment.

In response to the tax demand, Teva said, "The income tax claim is based on the groundless concept that acquiring companies by Teva is a dividend liable to tax. In Teva's opinion, and in line with an analysis by the best tax experts, this is an erroneous interpretation of the law and would be rejected by the courts if and when the matter is brought before them. Moreover, according to a professional opinion that we have obtained there is no need to set aside money for this assessment."

Teva added, "Teva has been exemplary in the application of the Law for the Encouragement of Capital Investment and the tax incentives stemming from it. Teva operates at 16 sites in Israel, factories and research centers, from Kiryat Shmona to Ramat Hovav. The company supports 10,000 families directly and a further 40,000 families indirectly. Teva's tax payments in its extended activities reach NIS 3 billion annually. In 2010, exports from Israel amounted to more than NIS 20 billion, and R&D investment was NIS 1.9 billion. Fixed capital investment was NIS 1 billion in 2010 and has totaled NIS 15 billion since 2000."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
November 13, 2018
Amazon to announce cities to build 'HQ2'